Cargando…

Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy

Background and Objectives: Subclinical atherosclerosis, reflected by abnormal carotid intima–media thickness (cIMT), is pervasive among chronic kidney disease patients on chronic renal replacement therapy (RRT), being mostly influenced by uremia-related rather than traditional risk factors. Material...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolignano, Davide, Greco, Marta, Arcidiacono, Valentina, Presta, Pierangela, Caglioti, Alfredo, Andreucci, Michele, Dragone, Francesco, Foti, Daniela Patrizia, Coppolino, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319800/
https://www.ncbi.nlm.nih.gov/pubmed/35888609
http://dx.doi.org/10.3390/medicina58070890
_version_ 1784755638238183424
author Bolignano, Davide
Greco, Marta
Arcidiacono, Valentina
Presta, Pierangela
Caglioti, Alfredo
Andreucci, Michele
Dragone, Francesco
Foti, Daniela Patrizia
Coppolino, Giuseppe
author_facet Bolignano, Davide
Greco, Marta
Arcidiacono, Valentina
Presta, Pierangela
Caglioti, Alfredo
Andreucci, Michele
Dragone, Francesco
Foti, Daniela Patrizia
Coppolino, Giuseppe
author_sort Bolignano, Davide
collection PubMed
description Background and Objectives: Subclinical atherosclerosis, reflected by abnormal carotid intima–media thickness (cIMT), is pervasive among chronic kidney disease patients on chronic renal replacement therapy (RRT), being mostly influenced by uremia-related rather than traditional risk factors. Materials and Methods: In this pilot study, we measured circulating levels of Omentin-1, a recently discovered adipokine with strong anti-atherogenic properties, in a heterogeneous cohort of 77 asymptomatic RRT individuals (40 chronic kidney transplant recipients, Ktx; and 37 chronic hemodialysis patients, HD) and in 30 age-matched controls. Results: Omentin-1 was increased in RRT individuals as compared with controls (p = 0.03). When stratifying for renal replacement modality, we found Ktx patients to have significantly lower Omentin-1 than HD patients (p = 0.01). Lower Omentin-1 levels were also found among RRT individuals with pathological cIMT (168.7 [51.1–457.8] vs. 474.9 [197.2–1432.1]; p = 0.004). Our multivariate correlations analysis revealed Omentin-1 as the most robust independent predictor of carotid atherosclerosis (β-0.687; p = 0.03), even more than total cholesterol, diastolic BP and age, and this adipokine was at the crossroad of a complex interplay with sustained inflammation (high CRP and ferritin) and hyperphosphatemia in predicting higher cIMT values. Conclusion: The findings reported extend to renal patients with advanced disease, with the possible involvement of Omentin-1 in the pathogenesis of atherosclerosis. This may set the stage for future interventional studies of Omentin-1 replacement to retard atherosclerosis progression, as it is currently being investigated in other disease settings.
format Online
Article
Text
id pubmed-9319800
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93198002022-07-27 Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy Bolignano, Davide Greco, Marta Arcidiacono, Valentina Presta, Pierangela Caglioti, Alfredo Andreucci, Michele Dragone, Francesco Foti, Daniela Patrizia Coppolino, Giuseppe Medicina (Kaunas) Brief Report Background and Objectives: Subclinical atherosclerosis, reflected by abnormal carotid intima–media thickness (cIMT), is pervasive among chronic kidney disease patients on chronic renal replacement therapy (RRT), being mostly influenced by uremia-related rather than traditional risk factors. Materials and Methods: In this pilot study, we measured circulating levels of Omentin-1, a recently discovered adipokine with strong anti-atherogenic properties, in a heterogeneous cohort of 77 asymptomatic RRT individuals (40 chronic kidney transplant recipients, Ktx; and 37 chronic hemodialysis patients, HD) and in 30 age-matched controls. Results: Omentin-1 was increased in RRT individuals as compared with controls (p = 0.03). When stratifying for renal replacement modality, we found Ktx patients to have significantly lower Omentin-1 than HD patients (p = 0.01). Lower Omentin-1 levels were also found among RRT individuals with pathological cIMT (168.7 [51.1–457.8] vs. 474.9 [197.2–1432.1]; p = 0.004). Our multivariate correlations analysis revealed Omentin-1 as the most robust independent predictor of carotid atherosclerosis (β-0.687; p = 0.03), even more than total cholesterol, diastolic BP and age, and this adipokine was at the crossroad of a complex interplay with sustained inflammation (high CRP and ferritin) and hyperphosphatemia in predicting higher cIMT values. Conclusion: The findings reported extend to renal patients with advanced disease, with the possible involvement of Omentin-1 in the pathogenesis of atherosclerosis. This may set the stage for future interventional studies of Omentin-1 replacement to retard atherosclerosis progression, as it is currently being investigated in other disease settings. MDPI 2022-07-02 /pmc/articles/PMC9319800/ /pubmed/35888609 http://dx.doi.org/10.3390/medicina58070890 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Bolignano, Davide
Greco, Marta
Arcidiacono, Valentina
Presta, Pierangela
Caglioti, Alfredo
Andreucci, Michele
Dragone, Francesco
Foti, Daniela Patrizia
Coppolino, Giuseppe
Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
title Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
title_full Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
title_fullStr Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
title_full_unstemmed Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
title_short Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
title_sort circulating omentin-1, sustained inflammation and hyperphosphatemia at the interface of subclinical atherosclerosis in chronic kidney disease patients on chronic renal replacement therapy
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319800/
https://www.ncbi.nlm.nih.gov/pubmed/35888609
http://dx.doi.org/10.3390/medicina58070890
work_keys_str_mv AT bolignanodavide circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT grecomarta circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT arcidiaconovalentina circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT prestapierangela circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT cagliotialfredo circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT andreuccimichele circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT dragonefrancesco circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT fotidanielapatrizia circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy
AT coppolinogiuseppe circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy